ceterum_censeo

9 ms·

31.
by ceterum_censeo 10y ago
> this smells a lot like apologetics. That's hardly my intention here, and frankly, I find the accusation both insulting and offensive. As with many (most?) pharmaceuticals, the cost of the active ingredient doesn't play a larg
32.
by ceterum_censeo 10y ago
If you're going to pull prices off Sigma, at the very least you should quote the USP grade. The cost of a pharmaceutical is not the raw material cost for the API, which is frequently a small fraction of the total cost. The majority of
33.
by ceterum_censeo 10y ago
> With respect to concerns about the list price of CDV, past price actions enabled the provision of consistent supply of a product with high carrying costs and very limited purchase volume of 200-300 units per year. The list price of CDV
34.
by ceterum_censeo 10y ago
I cynically thought that homeopathy was just distilled water, but then there is this: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/uc...
35.
by ceterum_censeo 10y ago
I'd like to hear your theories. Also, a few suggestions for the sites that you mention.
36.
by ceterum_censeo 10y ago
Would anyone who has experience using Cleanroom and PSP be willing to opine on the merits of both? I'm interested in lightweight but rigorous processes for improving software quality on regulated products, and both Cleanroom and PSP a
37.
by ceterum_censeo 10y ago
They did indeed have an investigative unit, but it was recently poached by CNN: http://www.politico.com/media/story/2016/10/cnn-hires-away-b... e: I don't recall any of their articles specifically,
38.
by ceterum_censeo 10y ago
Reading what you've written, it sounds like you are saying that Altman and people associated with YC are sufficiently petty that they would refuse to work with you in the future because of a political disagreement. Am I interpreting t
39.
by ceterum_censeo 10y ago
What repercussions? The situation strikes me as asymmetric: no matter what action Altman or Graham take they will be heavily criticized; for Ptacek, the worst would seem to be disagreement with his well-reasoned dialogue. It seems unfair t
40.
by ceterum_censeo 10y ago
> But we are all very much entitled to criticize what Altman is doing, and we would be doing Altman no favors by withholding that criticism. Why are you entitled to do it in the most publicly way you are able?
41.
by ceterum_censeo 10y ago
If Thiel donated $1.25M to the NRA, would this lead to the same calls for YC to distance themselves from Thiel? Where does this end?
42.
The SEC gets the case it’s been waiting for in Silicon Valley(techcrunch.com)
3 points by ceterum_censeo 10y ago|0 comments
43.
Zenefits, a Rocket That Fell to Earth, Tries to Launch Again(nytimes.com)
3 points by ceterum_censeo 10y ago|0 comments
44.
by ceterum_censeo 10y ago
> So far not a single investor has claimed that their DD team did not have access, that their DD team was competent to do the job in the first place and that the technology as evaluated was sound. This doesn't tell us one way or the
45.
by ceterum_censeo 10y ago
> Then please provide some proof that proper DD was done. If you are stating that "they [investors] failed to do due diligence", then the onus is on you to provide proof that the proper DD was done if you don't want your a
46.
by ceterum_censeo 10y ago
It doesn't strike me as charitable to take your strong stance that the investors were incompetent based on speculation with the benefit of hindsight. I agree that they would be negligent if they did not run DD with a scope that inclu
47.
by ceterum_censeo 10y ago
> they failed to do due diligence before investing Do we know the scope of the DD that was done?
48.
by ceterum_censeo 10y ago
It's hard to say exactly at what point it would be an appropriate read, but perhaps Knuth's The Art of Computer Programming should be on the reading list.
49.
by ceterum_censeo 10y ago
The EU strategy can solve regulatory problems seen in the US, but it introduces other problems to be solved: funding can become more difficult (although the normal rules wouldn't seem to apply to this group), import/export and tax
50.
by ceterum_censeo 10y ago
They had to run their own labs in order to take advantage of the laboratory developed test (LDT) regulatory framework. Selling their devices for others to use would have required FDA clearance. http://www.fda.gov/MedicalDevi